MAP2K1 and melanoma: In the present report, we further explored the influence of growth conditions on melanoma cells and cell response to treatment with vemurafenib (Zelboraf) targeting V600EBRAF and trametinib (Mekinist) targeting mitogen-activated kinase/ERK kinase 1/2 (MEK1/2).